The safety profile of belzutifan in renal tumors: real-world data from a tertiary academic center
The time to onset and severity of belzutifan AEs may differ between patients with VHL syndrome and spRCC. These findings suggest the need for a patient-centered approach to monitor and manage toxicity based on disease setting.
Authors
- Elizabeth Ryan (ORCID: https://orcid.org/0000-0001-9367-4204)
- Brian I. Rini (ORCID: https://orcid.org/0000-0002-2212-080X)
- Paulo Siqueira do Amaral
- Kathryn E. Beckermann (ORCID: https://orcid.org/0000-0002-4616-6140)
- Chiu-Lan Chen
- Morgan Lambrecht
- Aaron Winer
Institutions
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1093/oncolo/oyaf274
- Citations
- 1
- Primary Topic
- Cancer, Hypoxia, and Metabolism
- Type
- article
- Field-Weighted Citation Impact
- 0.94